Android app Apple app link

First subject enrolled in MUSC Hollings' Phase II/III trial of HNSCC treatment

By Yahoo! Finance   |   1 month ago
First subject enrolled in MUSC Hollings' Phase II/III trial of HNSCC treatment

The Medical University of South Carolina's Hollings Cancer Center initiates Phase II/III trial for treating HPV-negative head and neck cancer. The trial combines ficerafusp alfa and pembrolizumab to enhance patient outcomes by targeting resistance mechanisms and improving immune response.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.